S.Korea's FutureChem gets approval for phase 3 clinical trials in China

The company skipped phase 1 and 2 clinical trials and immediately received approval for phase 3

S.Korea's FutureChem gets approval for phase 3 clinical trials in China
Jeong Min Nam 1
2023-03-17 10:51:13 peux@hankyung.com
Bio & Pharma

South Korean radiopharmaceutical development company FutureChem Co. announced on Thursday that China's National Medical Products Administration (NMPA) has granted approval for a phase 3 clinical trial of its radiopharmaceutical drug FC303 for diagnosing prostate cancer in China.

Compared to conventional diagnostic techniques, FC303 is expected to more accurately locate microtumors and distantly metastasized prostate cancer. The latest approval came four months after the application for clinical trials in November last year.

Based on the positive results of phase 1 in Korea and the United States, the company skipped phase 1 and 2 clinical trials, and phase 3 was directly approved in China.

FutureChem plans to evaluate the diagnostic performance of FC303 positron emission tomography and computed tomography (PET-CT) imaging in 267 Chinese patients with medium-risk or higher prostate cancer.

In Sept. 2020, FutureChem signed an agreement with HTA Co. Ltd. to transfer FC303's copyright in China. HTA is the largest radiopharmaceutical company in China.

FutureChem plans to receive royalties of up to 16% of annual sales in China for 15 years, as well as part of the milestone payment following FC303's product approval.

Write to Jeong Min Nam at peux@hankyung.com
#FutureChem #FC303 #radiopharmaceuticals #prostate cancer #National Medical Products Administration #korea futurechem china #futurechem fc303 prostate

HLB’s Rivoceranib, Hengrui's Camrelizumab approved as combination therapy in China

HLB’s Rivoceranib, Hengrui's Camrelizumab approved as combination therapy in China

South Korea's HLB Co. announced on Thursday that the combination therapy of its drug candidate rivoceranib and Jiangsu Hengrui Pharmaceuticals Co., Ltd.’s (Hengrui Pharma) immuno-oncology drug camrelizumab was approved by the National Medical Products Administration (NMPA) as a first-lin

HK inno.N's K-CAB to get insurance benefits in China

HK inno.N's K-CAB to get insurance benefits in China

HK inno.N's K-CAB South Korea’s 30th novel medicine K-CAB Tab (active ingredient: tegoprazan), a gastroesophageal reflux disease (GERD) treatment of HK inno.N, will receive insurance coverage in China.According to industry sources on Thursday, K-CAB Tab was included in the National Reimbu

FutureChem seeks FDA nod for prostate cancer radiopharma trials

FutureChem seeks FDA nod for prostate cancer radiopharma trials

FutureChem is developing a prostate cancer treatment radiopharmaceutical FutureChem Co., a South Korean radiopharmaceutical company, is seeking the US Food and Drug Administration’s approval for clinical tests of its new drug for prostate cancer.The company, which recently completed the p
(* comment hide *}